My thoughts as well I have been following PCLO price I will be...

First 7 Last

Share
Profile

Follow
RAEJON

190 Posts.

1

17/07/19

13:01

Post #: 39561146
Share

Originally posted by superposition: ↑

Historically I have been a supporter of Creso Pharma, but I believe the CPH Board have well & truly stitched up retail investors with this deal, which was supposed to value CPH at A$0.63 per share. This would be the case if the deal was a cash for scrip deal. However the CPH share price has since been on the decline, currently trading at A$0.43, likely due to the fact that it's a scrip for scrip deal as is detailed in their company announcement on 7th June 2019 (see link below), and as the linked marketwatch article below notes;

'the purchase price for the Creso Pharma shares will be satisfied by the issuance of PharmaCielo common shares ("PharmaCielo Shares") priced at C$7.6166 per PharmaCielo Share being the 3-day volume weighted average trading price for the PharmaCielo Shares representing an exchange ratio of a 0.0775 PharmaCielo Shares per each Creso Pharma share'.If anyone has been monitoring PCLO, they would have seen that the share price has since devalued from C$7.61, and is today trading at C$5.33, which would likely explain the decline in the CPH share price over that period, and why it is now again trading at pre-deal prices.

I'll be voting "No" for this deal and in the absence of a much better offer!

https://www.asx.com.au/asxpdf/20190607/pdf/445p489rz7c4nq.pdf

https://www.marketwatch.com/press-release/pharmacielo-to-acquire-international-cannabis-company-creso-pharma-for-a122-million-2019-06-06?mod=mw_quote_news

Note: sentiment change from Buy to Hold, and a borderline Sell for me now with this deal.

Expand

My thoughts as well I have been following PCLO price I will be voting no unless something changes

CPH Price at posting: 43.0¢ Sentiment: Hold Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

With financials holding the fort, materials must step up with some heavy lifting to stimulate stocks

STX

Strike Energy secures $153 million for Perth Basin gas projects

BRX

Belararox delineates another porphyry in Argentina at Tambo South

EMD

Emyria's Empax Centre chosen for mental health clinical trial

SBW

Shekel Brainweigh CEO Nir Leshem weighs in on AI adoption ahead of FY25

Plagues precede widespread power shifts. We’re living in one – and minerals are at the fore

AML

Cultural heritage agreement puts Walford Creek exploration back on the map

RDN

If you thought lithium was dead, think again. The Pilbara will be central to the next upswing

ASX Market Update: Shares fall flat as GYG soars on debut | 20 June, 2024

FHE

Frontier Energy achieves key milestone for Waroona energy project